IPP Bureau
Progenesis opens genetic laboratory in New Delhi and AI & Bioinformatics data centre in Chennai
By IPP Bureau - December 13, 2023
Leading USA based genetic testing brand officially enters the Indian market
Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer
By IPP Bureau - December 12, 2023
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto
By IPP Bureau - December 12, 2023
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Zydus inks licensing agreement with Daewoong Pharmaceutical for leuprolide injectable in the US
By IPP Bureau - December 12, 2023
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
By IPP Bureau - December 12, 2023
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Briefs: GlaxoSmithKline Pharmaceuticals and Dr. Reddy's Laboratories
By IPP Bureau - December 10, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Pfizer presents marstacimab Phase 3 Data at ASH 2023
By IPP Bureau - December 10, 2023
Demonstrate significant bleed reduction in hemophilia A and B
Aptar Pharms opens new production facility at Taloja, Mumbai
By IPP Bureau - December 10, 2023
New facility is part of Aptar Pharma’s global expansion program
Astellas receives USFDA approval for expanded use of Cresemba for treatment of mucormycosis
By IPP Bureau - December 10, 2023
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346
By IPP Bureau - December 10, 2023
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Max Healthcare acquires 550 bedded Sahara Hospital, Lucknow
By IPP Bureau - December 09, 2023
This acquisition marks Max Healthcare's entry into Lucknow
Fire accident at Parmax Pharma’s plant
By IPP Bureau - December 09, 2023
There has been no loss or injury to human life
European Commission approves Pfizer’s Elrexfio for multiple myeloma
By IPP Bureau - December 09, 2023
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
By IPP Bureau - December 09, 2023
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Zepbound is now available in US for adults living with obesity
By IPP Bureau - December 09, 2023
Express Scripts to add Zepbound to National Preferred Formulary
